Pasithea Therapeutics (KTTA) Cash & Equivalents (2020 - 2026)

Pasithea Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $50.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 843.59% year-over-year to $50.4 million; the TTM figure through Mar 2026 stood at $50.4 million (up 843.59% YoY), while the FY2025 annual figure was $55.2 million, up 804.24% from the prior year.
• Cash & Equivalents came in at $50.4 million for Q1 2026 at Pasithea Therapeutics, down from $55.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $55.2 million in Q4 2025 to a low of $16634.0 in Q1 2023.
• A 5-year average of $23.0 million and a median of $13.4 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 99.97% in 2023 and surged 72041.4% in 2024, its largest moves.
• Pasithea Therapeutics' Cash & Equivalents stood at $33.1 million in 2022, then slumped by 59.5% to $13.4 million in 2023, then plunged by 54.48% to $6.1 million in 2024, then surged by 804.24% to $55.2 million in 2025, then retreated by 8.63% to $50.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $50.4 million, $55.2 million, and $4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison